Discriminant function based on hyaluronic acid and its degrading enzymes and degradation products for differentiating cirrhotic from non-cirrhotic liver diseased patients in chronic HCV infection

Clinica Chimica Acta

Volumn 369, Issue 1, 2006, Pages 66-72

  Attallah, Abdelfattah M ^a   Toson, El Shahat A ^b   El Waseef, Ahmad M ^b   Abo Seif, Mosaad A ^b   Omran, Mohamed M ^a   Shiha, Gamal E ^c  

^a Biotechnology Research Center of New Damietta   (Egypt)

^b Mansoura University   (Egypt)

^c MANSOURA UNIVERSITY   (Egypt)

Author keywords

Biomarkers; Blood; Cirrhosis; HCV; Hyaluronic acid; Liver

Indexed keywords

BIOCHEMICAL MARKER; HYALURONIC ACID; N ACETYL BETA GLUCOSAMINIDASE;

ADULT; ANALYTIC METHOD; ARTICLE; CLASSIFICATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISCRIMINANT ANALYSIS; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STANDARD; STATISTICAL ANALYSIS;

ADULT; BIOPSY; DISCRIMINANT ANALYSIS; FEMALE; GLUCOSAMINE; HEPATITIS C, CHRONIC; HUMANS; HYALURONIC ACID; LIVER CIRRHOSIS; MALE; MIDDLE AGED; ROC CURVE;

HEPATITIS C VIRUS;

EID: 33744456283     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.01.004     Document Type: Article

References (40)

1. Jenkins R.H., Thomas G.J., Williams J.D., and Steadman R. Myofibroblastic differentiation leads to hyaluronan accumulation through reduced hyaluronan turnover. J Biol Chem 279 (2004) 4153-4160
2. Meyer M.F., and Kreil G. Cells expressing the DG42 gene from early Xenopus embryos synthesize hyaluronan. Biochemistry 93 (1996) 4543-4547
3. Spicer A.P., and McDonald J.A. Characterization and molecular evolution of a vertebrate hyaluronan synthase gene family. Biol Chem 273 (1998) 1923-1932
4. Noble P.W. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol 21 (2002) 25-29
5. Gressner A.M. Liver fibrosis: perspectives in pathobiochemical research and clinical outlook. Eur J Clin Chem Clin Biochem 29 (1991) 293-311
6. Smedsrod B., Pertoft H., Eriksson S., Frasher R.E., and Laurent T.C. Studies in vitro on the uptake and degradation of serum hyaluranate in rate liver endothelial cells. J Biochem 223 (1984) 617-626
7. Masamune H., and Aizawa I. Biochemical studies on carbohydrates. Spectrophotometric determination of glucuronic acid in co-presence of galacturonic acid. Tohoku J Exp Med 65 (1957) 359-365
8. Isaksson A., and Hultberg B. Immunoassay of β-hexosaminidase isoenzymes in serum in patients with raised total activities. Clin Chim Acta 183 (1989) 155-162
9. Knodell R.G., Ishak K.G., Black W.C., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 (1981) 431-435
10. Aronson N.N., and Davidson E.A. Lysosomal hyaluronidase from rat liver: I. Preparation. J Biol Chem 242 (1967) 437-440
11. Stickel F., Urbaschek R., Schuppan D., et al. Serum collagen type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease. Dig Dis Sci 46 (2001) 2025-2032
12. Persico M., Palmentieri B., Vecchione R., Torella R., and De S.I. Diagnosis of chronic liver disease: reproducibility and validation of liver biopsy. Am J Gastroenterol 97 (2002) 491-492
13. Lu L.G., Zeng M.D., Wan M.B., et al. Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters. World J Gastroenterol 9 (2003) 2574-3578
14. Tengblad A. Quantitative analysis of hyaluronate in nanogram amounts. J Biochem 185 (1980) 101-105
15. Goldbarg J.A., Pineda E.P., Banks B.M., and Rutenburg A.M. A method for the colorimetric determination of beta-glucuronidase in urine, serum, and tissue; assay of enzymatic activity in health and disease. Gastroenterology 36 (1959) 193-201
16. Pugh D., Leaback D.H., and Walker P.G. Studies on glucosaminidase; N-acetyl-beta-glucosaminidase in rat kidney. Biochem J 65 (1957) 464-469
17. Hutterer F. Degradation of mucopolysaccharides by hepatic lysosomes. Biochim Biophys Acta 115 (1966) 312-319
18. Aminoff D., Morgan W.T., and Watkins W.M. 11. Studies in immunochemistry: the action of dilute alkali on the N-acetylhexosamines and the specific blood-group mucoids. J Biochem 51 (1952) 379-389
19. Morgan W., and Elson L. Colorimetric determination of the N-acetylhexosamines. J Biochem 28 (1934) 988-992
20. Johnson A.R. Improved method of hexosamine determination. Anal Biochem 44 (1971) 628-635
21. Nir I. Determination of glucuronic acid by naphthoresorcinol. Anal Biochem 8 (1964) 20-23
22. McHutchison J.G., Blatt L.M., de Medina M., et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus interferon study group. J Gastroenterol Hepatol 15 (2000) 945-951
23. Afdhal N.H. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests?. Hepatology 37 (2003) 972-974
24. Cadranel J.F., Rufat P., and Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the group of epidemiology of the French association for the study of the liver (AFEF). Hepatology 32 (2000) 477-481
25. Forns X., Ampurdanes S., Llovet J.M., et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36 (2002) 986-992
26. Wai C.T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 (2003) 518-526
27. Saitou Y., Shiraki K., Yamanaka Y., et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 11 (2005) 476-481
28. Plevris J.N., Haydon G.H., Simpson K.J., et al. Serum hyaluronan-a non-invasive test for diagnosing liver cirrhosis. Eur J Gastroenterol Hepatol 12 (2000) 1121-1127
29. Luo R., Yang S., Xie J., Zhao Z., He Y., and Yao J. Diagnostic value of five serum markers for liver fibrosis. Zhonghua Gan Zang Bing Za Zhi 9 (2001) 148-150
30. Murawaki Y., Ikuta Y., Idobe Y., Koda M., and Kawasaki H. Molecular weight of hyaluronate in the serum of patients with chronic liver disease. Res Commun Mol Pathol Pharmacol 99 (1998) 207-216
31. Gressner A.M., and Bachem M.G. Cellular sources of noncollagenous matrix proteins: role of fat-storing cells in fibrogenesis. Semin Liver Dis 10 (1990) 30-46
32. Patel K., Lajoie A., Heaton S., et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 18 (2003) 253-257
33. Murata K., Ochiai Y., and Akashio K. Polydispersity of acidic glycosaminoglycan components in human liver and the changes at different stages in liver cirrhosis. Gastroenterology 89 (1985) 1248-1257
34. Tangkijvanich P., Kongtawelert P., Pothacharoen P., Mahachai V., Suwangool P., and Poovorawan Y. Serum hyaluronan: a marker of liver fibrosis in patients with chronic liver disease. Asian Pac J Allergy Immunol 21 (2003) 115-120
35. Lackner C., Struber G., Liegl B., et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 41 (2005) 1376-1382
36. Fortunato G., Castaldo G., Oriani G., et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 47 (2001) 1696-1700
37. Giannini E., Botta F., Testa E., et al. The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. Am J Gastroenterol 97 (2002) 2855-2860
38. Adams L.A., Bulsara M., Rossi E., et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 51 (2005) 1867-1873
39. Poynard T., Imbert-Bismut F., Munteanu M., et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 3 (2004) 8
40. Halfon P., Bourliere M., Penaranda G., et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 4 (2005) 6